[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Neurogene Inc (NGNE)

Neurogene Inc (NGNE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 626,233
  • Shares Outstanding, K 15,802
  • Annual Sales, $ 0 K
  • Annual Income, $ -90,350 K
  • EBIT $ -111 M
  • EBITDA $ -112 M
  • 60-Month Beta 1.68
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.51

Options Overview Details

View History
  • Implied Volatility 98.35% (-0.57%)
  • Historical Volatility 77.26%
  • IV Percentile 2%
  • IV Rank 0.99%
  • IV High 248.71% on 02/13/26
  • IV Low 96.85% on 11/26/25
  • Expected Move (DTE 6) 1.87 (4.72%)
  • Put/Call Vol Ratio 0.05
  • Today's Volume 87
  • Volume Avg (30-Day) 125
  • Put/Call OI Ratio 0.18
  • Today's Open Interest 2,356
  • Open Int (30-Day) 1,965
  • Expected Range 37.76 to 41.50

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-1.39
  • Number of Estimates 4
  • High Estimate $-1.30
  • Low Estimate $-1.44
  • Prior Year $-1.05
  • Growth Rate Est. (year over year) -32.38%

Price Performance

See More
Period Period Low Period High Performance
1-Month
27.75 +42.81%
on 06/11/26
43.66 -9.23%
on 07/09/26
+11.62 (+41.49%)
since 06/10/26
3-Month
19.13 +107.15%
on 04/13/26
43.66 -9.23%
on 07/09/26
+19.25 (+94.46%)
since 04/10/26
52-Week
15.93 +148.78%
on 02/05/26
43.66 -9.23%
on 07/09/26
+17.67 (+80.46%)
since 07/10/25

Most Recent Stories

More News
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation...

NGNE : 39.63 (-7.49%)
Neurogene Inc. Announces Pricing of $125 Million Public Offering

Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced the pricing of...

NGNE : 39.63 (-7.49%)
Neurogene Inc. Announces Proposed Public Offering

Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that it has commenced...

NGNE : 39.63 (-7.49%)
Neurogene Reports Positive Long-term Clinical Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome

4 7 total developmental milestones gained across 10 participants, with durable treatment effect and no plateau or milestone loss through 30 months of follow-up ...

NGNE : 39.63 (-7.49%)
Neurogene Announces Successful Completion of Dosing in Emboldenâ„¢ Registrational Trial of NGN-401 for Rett Syndrome

Exceeded target by dosing a total of 25 participants with NGN-401 in registrational trial due to strong demand from Rett syndrome community NGN-401 has been generally...

NGNE : 39.63 (-7.49%)
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Neurogene Inc. (Nasdaq: NGNE), a clinical-stage company founded to bring life-changing genetic medicines to patients and families affected by rare neurological diseases, today announced that the Compensation...

NGNE : 39.63 (-7.49%)
Neurogene: Q1 Earnings Snapshot

Neurogene: Q1 Earnings Snapshot

NGNE : 39.63 (-7.49%)
Neurogene Reports First Quarter 2026 Financial Results and Highlights Recent Updates

Dosed ~90% of participants in Emboldenâ„¢ registrational trial of NGN-401 for Rett syndrome; on track to complete dosing in the second quarter of 2026 NGN-401 has been...

NGNE : 39.63 (-7.49%)
Neurogene Highlights Data at ASGCT Meeting Supporting Therapeutic Rationale for ICV Delivery Method in CNS-targeted Gene Therapy

ICV is a commonly used neurosurgical procedure performed across multiple therapeutic settings, including gene therapy Presentation adds to body of evidence that ICV administration...

NGNE : 39.63 (-7.49%)
Neurogene Reports Before the Market Opens With Analysts Expecting More of the Same

Barchart Research What to Expect from NGNE Earnings NGNE Generated May 7, 2026 Current Price $31.26 EPS Estimate $$-1.35 Consensus Rating Strong Buy Average Move 9.72% Neurogene Reports Before the Market...

NGNE : 39.63 (-7.49%)

Business Summary

Neurogene Inc. is a clinical-stage company which bring life-changing genetic medicines to patients and families affected by rare neurological diseases. Neurogene Inc., formerly known as Neoleukin Therapeutics Inc., is based in NEW YORK.

See More

Key Turning Points

3rd Resistance Point 47.18
2nd Resistance Point 45.09
1st Resistance Point 42.36
Last Price 39.63
1st Support Level 37.54
2nd Support Level 35.45
3rd Support Level 32.72

See More

52-Week High 43.66
Last Price 39.63
Fibonacci 61.8% 33.07
Fibonacci 50% 29.80
Fibonacci 38.2% 26.52
52-Week Low 15.93

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.